文献速递真菌感染新发突发、热带与寄生虫病

新型芳基脒T-2307对格特隐球菌的体内外抗真菌活性

In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

本研究评估新型芳基脒T-2307对新兴致病真菌格特隐球菌的体内外活性,并与两性霉素B、氟康唑和伏立康唑比较。体外对15株临床分离株的MIC显著低于对照药物,小鼠肺部感染模型中T-2307在感染后14天给药仍能显著降低肺和脑组织活菌数。T-2307有望成为隐球菌病治疗的新候选药物。

要点

  • T-2307对格特隐球菌临床分离株的MIC范围为0.0078-0.0625 mg/L
  • T-2307在4倍MIC及以上呈浓度依赖性杀菌活性
  • 感染后14天给药,仅T-2307 1 mg/kg/天显著降低肺和脑活菌数

核心结论

  • T-2307对格特隐球菌表现出优异的体内外抗真菌活性,有望成为隐球菌病治疗的新候选药物。

研究设计与样本

  • 体外药敏试验采用CLSI指南测定15株格特隐球菌临床分离株的MIC,并进行时间-杀菌研究。
  • 体内实验采用格特隐球菌YF2784鼻内肺部感染小鼠模型,从感染后2小时或14天开始每日给药一次、持续7天,感染后21天测定肺和脑组织活菌数。

主要发现

  • T-2307对15株临床分离株的MIC范围、MIC50、MIC90和几何平均MIC分别为0.0078-0.0625、0.0313、0.0625和0.0394 mg/L。
  • T-2307的MIC显著低于氟康唑、伏立康唑和两性霉素B。
  • T-2307在4倍MIC或更高浓度下显示浓度依赖性杀菌活性。
  • 感染后2小时开始给药,T-2307 2 mg/kg/天、两性霉素B 1 mg/kg/天和氟康唑160 mg/kg/天均显著降低肺和脑组织活菌数。
  • 感染后14天开始给药,仅T-2307 1 mg/kg/天显著降低肺和脑组织活菌数。

临床怎么用

  • 对于格特隐球菌感染,T-2307体外活性优于氟康唑、伏立康唑和两性霉素B。
  • 在延迟治疗(感染后14天)的动物模型中,T-2307仍显示肺和脑组织清除效果,提示潜在治疗价值。

局限性

  • 研究仅使用15株临床分离株和单一菌株的小鼠模型,样本量有限。
  • 尚未报告药代动力学、毒理学及临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: T-2307, a novel arylamidine, exhibits potent broad-spectrum activities against the majority of fungal pathogens. In this study, the antifungal activity of T-2307 against Cryptococcus gattii was evaluated in comparison with those of amphotericin B, fluconazole and voriconazole in vitro and in vivo . METHODS: The MICs for 15 clinical isolates were determined according to CLSI guidelines and time-kill studies were performed using C. gattii YF2784. In a murine model for intranasal pulmonary infection caused by C. gattii YF2784, the test compounds were administered once daily for 7 days from 2 h or 14 days post-infection. The viable counts in the lungs and brain were determined at 21 days post-infection. RESULTS: The MIC range, MIC 50 , MIC 90 and geometric mean MIC of T-2307 were 0.0078-0.0625, 0.0313, 0.0625 and 0.0394 mg/L, respectively. The MIC of T-2307 was significantly lower than those of fluconazole, voriconazole and amphotericin B. T-2307 showed concentration-dependent fungicidal activity at 4 times the MIC or higher. Administration of T-2307 at 2 mg/kg/day, amphotericin B at 1 mg/kg/day and fluconazole at 160 mg/kg/day from 2 h post-infection significantly reduced viable counts in the lungs and brain. However, when the administration was started 14 days post-infection, only T-2307 significantly reduced the viable counts in both the lungs and the brain at 1 mg/kg/day. CONCLUSIONS: T-2307 shows excellent in vitro and in vivo antifungal activities against C. gattii and would be a promising new candidate for the treatment of cryptococcosis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Nishikawa H, Fukuda Y, Mitsuyama J, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen. J Antimicrob Chemother. 2017. PMID: 28201509. doi:10.1093/jac/dkx020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。